GE Healthcare Technologies Inc (GEHC) Stock Analysis
Verdict: BUY
Low-valuation diagnostic incumbent expanding into high-margin AI/radiopharma faces debt overhang and mixed earnings execution.
Investment score: 67/100
Analysis as of
Is GE Healthcare Technologies Inc stock worth reviewing? AI model thesis
The model identifies GEHC as a strong fundamental value opportunity trading at 18.60x P/E with a 21.6% upside to consensus analyst targets ($78.73).
7-factor investment score
- Valuation: 78/100 (weight 20%)
- Financial Health: 65/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 85/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 70/100 (weight 15%)
GE Healthcare Technologies Inc opportunities and risks
What speaks for GEHC
- Steep relative valuation discount vs medtech peers
What speaks against GEHC
- Elevated balance sheet debt restricts capital allocation flexibility
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| GEHC | 18.6x | 1.4x | 10.7x | 42.9% | 7.9% | 3.1% |
| EW | 50.8x | 7.8x | 31.6x | 78.0% | 15.4% | 2.8% |
| BDX | 55.3x | 2.4x | 17.1x | 46.1% | 4.5% | 5.2% |
| IDXX | 35.9x | 8.9x | 25.5x | 62.4% | 25.0% | 3.1% |
| DXCM | 34.0x | 6.7x | 21.5x | 62.5% | 20.1% | 4.2% |
| RMD | 21.8x | 5.8x | 15.1x | 61.2% | 26.9% | 8.8% |
| Peer median | 35.9x | 6.7x | 21.5x | 62.4% | 20.1% | 4.2% |
Frequently asked questions about GE Healthcare Technologies Inc (GEHC)
Is GEHC stock a good investment?
The cached TradeMates AI model rates GE Healthcare Technologies Inc as BUY with an investment score of 67/100. The model identifies GEHC as a strong fundamental value opportunity trading at 18.60x P/E with a 21.6% upside to consensus analyst targets ($78.73). This is algorithmic model output, not personal investment advice.
Is GEHC stock a buy?
The TradeMates model verdict for GEHC is BUY with an investment score of 67/100. Treat this as a model signal to review, not a personal buy recommendation.